Jun 20 |
Alto Neuroscience Initiates Phase 2 Study of ALTO-101, a Novel PDE4 Inhibitor, in Cognitive Impairment Associated with Schizophrenia
|
Jun 18 |
Amit Etkin, M.D., Ph.D., Founder and CEO of Alto Neuroscience, Named an EY Entrepreneur Of The Year® 2024 Bay Area Award Winner
|
May 29 |
Alto Neuroscience to Present at the Jefferies Global Healthcare Conference
|
May 21 |
Alto Neuroscience appoints Michael Hanley as COO
|
May 21 |
Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer
|
May 15 |
Alto Neuroscience reports Q1 GAAP EPS of -$0.76
|
May 14 |
Alto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business Highlights
|
May 9 |
Alto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific Conferences
|
Apr 23 |
Alto Neuroscience schizophrenia treatment shows good phase 1 results
|
Apr 23 |
Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia
|